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Karin Eijkelenkamp1 • Thamara E. Osinga1 • Mirjam M. de Jong2 •
Wim J. Sluiter1 • Robin P. F. Dullaart1 • Thera P. Links1 • Michiel N. Kerstens1 •
Anouk N. A. van der Horst-Schrivers1
 The Author(s) 2016. This article is published with open access at Springerlink.com
Abstract Germline mutations of the gene encoding suc-
cinate dehydrogenase subunit B (SDHB) predispose to
head-and-neck-paraganglioma (HNPGL), sympathetic
PGL, pheochromocytoma and renal cell carcinoma for
which regular surveillance is required. SDHB-associated
tumors harbor germline and somatic mutations, consistent
with Knudson’s two-hit hypothesis. To assess the pene-
trance and optimal surveillance for different manifestations
of SDHB mutation carriers. This study included all SDHB
mutation carriers who were followed at the Department of
Endocrinology at the University Medical Center of
Groningen. Kaplan–Meier curves were used to assess the
penetrance. Poisson process was used to assess the optimal
age to start surveillance and intervals. Ninety-one SDHB-
mutation carriers (38 men and 53 women) were included.
Twenty-seven mutation carriers (30 %) had manifestations,
with an overall penetrance 35 % at the age of 60 years. We
calculated that optimal surveillance for HNPGL could start
from an age of 27 years with an interval of 3.2 years. This
study underscores the relatively low penetrance of disease
in SDHB mutation carriers. Use of the Poisson approach
provides a more accurate estimation of the age to initiate
surveillance and length of intervals for HNPGL. These
results may give rise to reconsider the current guidelines
regarding the screening of these mutation carriers.
Keywords Paraganglioma  Pheochromocytoma  SDHB
mutation carriers  Surveillance
Introduction
The succinate dehydrogenase subunit B (SDHB) gene is
one of the 15 [1] susceptibility genes that have been linked
to familial paraganglioma (PGL) and pheochromocytoma
(PCC) [2]. Germline mutations in this gene predispose to
head and neck paragangliomas (HNPGLs), sympathetic
PGLs and PCCs. HNPGLs are mainly nonsecretory tumors
of the parasympathetic paraganglia in the head and neck
region, whereas sympathetic PGLs and PCCs are known
for overproduction of catecholamines. Because of
increased risk of developing HNPGLs, sympathetic PGLs
and PCC, SDHB mutation carriers require regular surveil-
lance, which consists of determination of plasma and/or
urine metanephrines and performance of magnetic reso-
nance imaging (MRI) at regular intervals (Table 1) [3–8].
According to the current literature, the mean age upon
diagnosis of a manifestation in SDHB mutation carriers is
30–35 years [9]. Various surveys report considerable dif-
ferences in disease penetrance ranging from 8 to 55 % at
the age of 40 years [7–12]. A mutation in the SDHB gene is
also associated with a high risk of the development of
malignant PGLs, varying from 17 to 71 % [7, 8, 12–14]. In
addition, SDHB mutation carriers have been associated
with an increased risk of developing other neoplasms,
including renal cell carcinoma, gastrointestinal stromal
tumors (GISTs) and papillary thyroid cancer [9]. Until
today, no international consensus has been developed
regarding the optimal mode of surveillance for SDHB
mutation carriers. The Dutch national guideline advises to
screen SDHB mutation carries as early as from the age of
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18 years, including annual physical examination, bio-
chemical testing for catecholamine excess (plasma/urinary
metanephrines) and regular imaging of the head and neck
and thoracic-abdominal-pelvic region [3]. These recom-
mendations correspond to international guidelines, except
for the age of starting surveillance and the subsequent
intervals (Table 1).
SDHB-associated tumors harbor germline and somatic
mutations, consistent with Knudson’s two-hit hypothesis
[15]. This hypothesis states that the combination of an
inactivating germline mutation as a first hit and somatic
loss of function of the wild type allele as a second hit is
essential for tumor development [16, 17].
Recently, Knudson’s two hit hypothesis has been used
with von Hippel Lindau (VHL) mutation carriers to calculate
time-to-detection of the first and subsequent VHL-related
manifestations [18]. This model could also provide a ratio-
nale to define the age to start surveillance and subsequent
surveillance intervals in patients with SDHB mutations. This
would allow for evidence-based decisions as to the age to
start surveillance in patients with a SDHB mutation and the
length of the subsequent surveillance intervals. Therefore,
the aim of this study was to assess the penetrance and optimal
surveillance for different manifestation of SDHB mutation
carriers, using a Poisson distribution model.
Patients and methods
Study population
All SDHB mutation carriers undergoing surveillance at the
Endocrinology department of the University Medical
Center Groningen (UMCG) between 2008 (establishment
of guidelines for surveillance) and July 2015, were inclu-
ded in this study. The index patients of a SDHB-carrier
family were also included when known at the UMCG.
Screening of SDHB mutation carriers was performed
according to Dutch surveillance guidelines, consisting of
physical examination and measurements of plasma/urinary
metanephrines every year, MRI of the head and neck
region every 3 years and MRI of the thoracic-abdominal-
pelvic region every 2 years [3].
Demographics and clinical data including the type of
mutation, tumor characteristics, symptoms, blood pressure,
biochemistry, radiologic imaging records (original report)
and treatment were collected from the medical charts.
Manifestations were classified as either HNPGL (carotid-,
jugular/tympanic- or vagal body), sympathetic PGL (tho-
racic, abdominal or pelvic PGL) or PCC The presence of a
primary manifestation or metastases was confirmed histo-
logically or based on a combination of persistently elevated
plasma/urinary metanephrines (in case of a sympathetic
PGL or PCC) and functional imaging including 111In-oc-
treotide scintigraphy (octreoscan), 123I-metaiodobenzyl-
guanidin (MIBG scintigraphy) and/or 6-[18F]-fluoro-L-3,4-
dihydroxyphenylalanine (DOPA) positron emission
tomography (PET) and/or anatomical imaging (Computed
Tomography (CT) and/or MRI). Carriers who developed a
manifestation were classified as disease ‘‘affected carri-
ers’’; i.e. either index patients or carriers who developed a
manifestation detected during follow-up. Carriers were
classified as ‘‘unaffected’’ when there was no evidence of a
HNPGL, sympathetic PGL or PCC on the last performed
imaging. Other neoplasms were also recorded when his-
tological proven.
According to the Dutch Medical Research Involving
Human Subjects Act, no further Institutional Review Board







Anatomical imaging Functional imaging
Kirmani et al. [4] 10a Annual CT/MRI of skull base and neck every
2 years, MRI of TAP every 4 years
123I-MIBG every 4 years
Benn et al. [8] 10 Annual CT and/or MRI neck and TAP every 2 years Consider 18F-DOPA-PET
Neumann et al. [6] Not reported Annual Annual MRI of neck and TAP Consider 18F-DOPA-PET
Srirangalingam et al. [7] 5 Annual Annual MRI of neck and TAP
Dutch guideline [3] 18 Annual MRI of TAP every 2 years
MRI of head and neck every 3 years
Taı¨eb et al. [5] Not reported Annual MRI of head and neck every 3 years PET should be discussed on
individual cases
SDHB succinate dehydrogenase sununit B, CT computed tomography, MRI magnetic resonance imaging, 123I-MIBG 123metaiodobenzylguanine,
18FDOPA-PET 6-[18F]-fluoro-L-3,4-dihydroxyphenylalanine positron emission tomography, TAP thoracic-abdominal-pelvic region
a Or at least 10 years before earliest age at diagnosis in the family
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approval was required, because we used existing clinical
data already collected for regular patient care. The identity
of the subjects was protected by using unique codes which
were only known to the principal investigator.
Measurement of urinary and plasma metanephrines
Isotope-dilution mass spectrometry based measurements of
urinary metanephrines [metanephrine (MN), normetanephri-
nes (NMN) and 3-methoxytyramine (3-MT)] were used, with
the following reference intervals: MN 33–99 lmol/mol cre-
atinine, NMN 64-260 lmol/mol creatinine, 3-MT 45–
197 lmol/mol creatinine. Plasma free metanephrines assays
were performed with a High-Performance Liquid Chro-
matography tandem mass spectrometric technique (LC–MS/
MS) with automated solid phase extraction sample prepara-
tion, as described by de Jong et al. [19]. Reference intervals for
plasma free metanephrines were: MN 0.07–0.33 nmol/L,
NMN 0.23–1.07 nmol/L, 3-MT \0.17 nmol/L. Elevated
plasma/urinary metanephrines were defined as a value above
the upper reference limit.
Imaging
MRI scans of head and neck region were performed on a
1.5 Tesla scanner with 4 mm coronal and axial pre- and
postcontrast T1-weighted sequences covering the posterior
skull base and neck, as well as a dynamic contrast-en-
hanced MRA from aortic arch to skull base. MRI scans of
thoracic-abdominal region were performed on a 1.5 Tesla
scanner with coronal and transversal T1- and T2-weighted
sequences without contrast.
Functional imaging (octreoscan, MIBG scintigraphy or
DOPA-PET) was performed in all patients with sympa-
thetic PGL and or PCC. It was also used in patients with
HNPGL to specify the nature of the lesion found on MRI
when the original report was inconclusive.
Statistical analyses
Data are presented as mean ± standard deviation (SD) or
as median with interquartile range [IQR] or range. Pene-
trance for the different manifestations of disease was
determined using the reverse Kaplan–Meier method. For
unaffected carriers the last follow-up date was defined as
follows: date of the last negative imaging of head and neck
region in case of HNPGL, and date of last negative
imaging of thoracic-abdominal-pelvic region for sympa-
thetic PGL and PCC.
Because including index patients is likely to bias
towards a younger diagnosis and therefore affect the esti-
mation of penetrance, we performed the statistical analysis
both with and without the index patients. The log rank test
was used to compare the penetrance between different
genotypes.
The Poisson distribution model was used to calculate the
probability of detection of a manifestation over time. As
alluded to above, SDHB-related tumors are supposed to be
consistent with Knudson’s two hit hypothesis, suggesting
that the second hit (i.e. loss of the wild type allele and
consequently to the development of a tumor) occurs at
random [15, 17].
A linear regression analysis of this model was used to
estimate the incidence j (hit rate) of developing a mani-
festation. The time between the second hit and the detection
of the tumor is called delay (d). This time was assessed from
the intercept of the natural logarithm (ln) of 1-cumulative
proportion with the age axis. Only calculated cumulative
proportions expected to follow the straight part of the line
are used for the linear regression analyses. The initial part,
set arbitrarily to below 3 %, will necessarily deviate from
the straight line because of the variance in delay and is thus
omitted in this analysis. The optimal age to start surveil-
lance was calculated from the delay (d) minus 2 * SD, the
lower end of the 95 % confidence interval of the estimated
delay. In this matter, a safe boundary was established with a
negligible risk of a manifestation below this age of starting
surveillance. The surveillance interval was defined by
0.1 * 1/j, defining a 10 % change for the detection of a new
tumor within this interval. This interval was calculated also
for the proportions 5 and 1 %.
A two sided P value\0.05 was considered statistically
significant. Statistical analyses were performed with




Ninety-one carriers from 24 non-consanguineous families
with a SDHB mutation were seen at the Department of
Endocrinology between 2008 and 2015. Of these 91 car-
riers, 21 (23 %) were index patients. Twenty-seven carriers
(30 %) were disease affected at the time of analysis. Eight
different mutations in the SDHB gene were documented.
Characteristics of mutation carriers are listed in Table 2.
Median of follow-up of all carriers combined was 3.3
[IQR 2.2–4.5] years. Median follow-up for disease affected
carriers (index patients and patients with manifestations
detected during surveillance) and for unaffected carriers
was 3.7 years [IQR 2.3–11.3] and 3.1 years [IQR 2.1–4.1],
respectively. Three patients (all index patients) died during
follow-up, due to malignant sympathetic PGLs. In three
patients (3 %) no imaging of head and neck region was
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available at the end of follow-up (i.e. July 2015) and were
therefore excluded for the calculation of the penetrance of
HNPGL.
Penetrance of HNPGLs
Nineteen SDHB mutation carriers were diagnosed with a
HNPGL (n = 13 index patients, n = 6 detected during
surveillance) (Table 2). These six HNPGL were detected
by imaging during surveillance. Only one patient had an
elevated plasma NMN level at the same time the imaging
was performed. The penetrance of this manifestation,
including all carriers, was 8 % at the age of 40 and 32 % at
the age 60 years. When we excluded the index patients, the
penetrance was 2 % at age 40 and 14 % at age 60 years
(Fig. 1). No differences in penetrance were found between
the most common mutations deletion exon 3 (n = 11) and
c.653G[A (n = 5) (P = 0.787). The mutations c.654G[A
(n = 1), c.292T[C (n = 1), c.725G[A (n = 1) were
excluded for comparison due to the low number of patients.
The median age at diagnosis of a HNPGL was 45 [IQR
38–55, range 26–68] years. Tumors were located in the
carotid-(n = 10), jugular/tympanic-(n = 6) and vagal body
(n = 3). Three patients had multiple HNPGLs. Two of
these patients developed metastases, 31 and 22 years after
the initial diagnosis of HNPGL.
Penetrance of sympathetic PGLs and PCCs
Nine SDHB mutation carriers (all index patients), were
diagnosed with a sympathetic PGL or PCC (Table 2). The
mutations were: deletion exon 3 (n = 5), c.654G[A
Table 2 Patient characteristics
of SDHB mutation carriers
SDHB mutation
carriers (n = 91)
Sex (male/female) 38/53
Index patients 21 (23 %)
Disease affected carriers 27 (30 %)
Mean age at first visit in years (±SD) 44 (±15)
Median duration of follow-up in years [IQR] 3.3 [2.2–4.5]
Median duration of follow-up in years [IQR],
disease affected carriers
3.7 [2.3–11.3]
Median duration of follow-up in years [IQR],
unaffected carriers
3.1 [2.1–4.1]
Manifestations of disease affected carriers
HNPGL 19 (20 %)
Sympathetic PGL/PCC 9 (10 %)
Median age of diagnosis in years [IQR]
HNPGL 45 [38–55]
Sympathetic PGL/PCC 19 [17–36]
Biochemical profiles of disease affected carriersa
Silent tumors 16 (57 %)
Elevated normetanephrine 8 (29 %)
Elevated metanephrine 2 (7 %)
Elevated 3-MT 5 (18 %)
Malignant PGL 8 (9 %)
Mutations in SDHB-gene
Deletion exon 3 44 (48 %)
c.654G[A 25 (27 %)
c.653G[A 14 (15 %)
c.649C[T 1 (2 %)
c.292T[C 4 (4 %)
c.268C[T 1 (1 %)
c.73?-200? 1 (1 %)
c.725G[A 1 (1 %)
SDHB succinate dehydrogenase subunit B, HNPGL head and neck paraganglioma, PGL paraganglioma,
PCC pheochromocytoma, SD standard deviation, IQR interquartile range, 3-MT 3-methoxytyramine
a The biochemical profile of one patient is missing
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(n = 2), c.653G[A (n = 1), c.268G[A (n = 1). The
penetrance of this manifestation was estimated to be 10 %
at age 40 years and 10 % at age 60 years. Calculation of
the penetrance after exclusion the index patients, or com-
parison of the penetrance according to the different types of
mutation was not feasible due to the low number of
patients. The median age at diagnosis was 19.7 years [IQR
17–36, range 11–66]. All sympathetic PGLs were located
in the abdominal or pelvic region, mostly in the para-aortal
region. One PGL was located in the organ of Zuckerkandl
and one in the urinary bladder. Six out of the nine patients
(67 %) with a sympathetic PGL or PCC developed
metastases. Four patients presented with metastases, and an
additional two patients developed metastases 4 and
39 years after the initial diagnosis of sympathetic PGL.
Penetrance of all manifestations
Twenty-seven SDHB mutation carriers (30 %) had a
manifestation either at initial presentation (index patient,
n = 21) or during follow-up (n = 6); overall penetrance
(including the index patients) was 18 % at the age of
40 years and 35 % at the age of 60 years (Fig. 2). Overall
penetrance without index patients was 2 % at age 40 and
12 % at age 60. No significant difference in penetrance was
found between the three most common mutations (deletion
exon 3, c.654G[A and c.653G[A) (P = 0.242). Because
of the low number of patients, mutations in codon 649, 292,
268 and 725 were excluded from comparisons. The mani-
festations of each specific mutation are reported in Table 3.
The median age at diagnosis of the first manifestation was
39 years [IQR 28–51, range 11–68]. The oldest clinically
unaffected subject was 77 years of age.
Optimal surveillance
The optimal age to start surveillance with subsequent
intervals was calculated for HNPGLs. A linear correlation
was found between the ln 1-cumulative proportion and the
age of first HNPGL (r Pearson: 0.98), corresponding to the
Poisson process (Fig. 3). The incidence rate (j) of this
manifestation was 1.6 % per year. The mean delay between
the second hit and detection of the tumor (d) was
32.7 years (95 % CI 27.1–38.3). As a result, the optimal
age to start screening for this manifestation would be
27.1 years. Subsequent intervals were 6.6, 3.2 and
0.6 years for a detection probability of 10, 5 and 1 %,
respectively. Therefore the chance to detect a HNPGL is
10, 5 or 1 % when using an interval van 6.6, 3.2 or
0.6 years respectively. The optimal surveillance for sym-
pathetic PGLs and PCCs could not be assessed due to low
number of patients.
Other neoplasms
In addition to the patients diagnosed with a (HN)PGL or
PCC, several other manifestations were reported in this
cohort of SDHB mutation carriers. In two carriers (2 %)
(one unaffected carrier and one index patient with a
HNPGL) pituitary tumors were present: one non-func-
tioning microadenoma and one microprolactinoma. Three
SDHB mutation carriers (3 %) had a non-hypersecreting
adrenal adenoma, either based on the pathology report
(n = 1), or based on MRI and scintigraphic findings in
combination with normal levels of plasma metanephrines
(n = 2). Renal cysts were present in six (four unaffected
carriers and two index patients) carriers (7 %). Other
(histologically proven) neoplasms included cervical
Fig. 1 Age-related penetrance of succinate dehydrogenase subunit B
mutation carriers with a head and neck paraganglioma (HNPGL),
including index cases (black line), and excluding index cases (dotted
line)
Fig. 2 Age-related penetrance of all manifestations (head and neck
paraganglioma, sympathetic paraganglioma and pheochromocytoma)
of the succinate dehydrogenase subunit B-gene including index cases
(black line) and excluding index patients (dotted line)
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carcinoma (n = 1; unaffected carrier) and melanoma
(n = 1; index patient with HNPGL). No renal cell carci-
noma, thyroid malignancy, or gastrointestinal stromal
tumors was diagnosed in these carriers.
Discussion
This is the first study using the Poisson distribution model
to calculated the time to detect the first and subsequent
HNPGL in SDHB mutation carriers. This mathematical
model provides a rationale to assess the optimal age to start
surveillance at 27 years and subsequent follow-up intervals
at 3 years. This approach also has been recently applied to
calculate the optimal surveillance in patients with a
mutation in the VHL-gene [18]. The outcome is compatible
with the assumption of the two-hit hypothesis used in our
model, which is a statistical proof that the Poisson distri-
bution model is a valid method to use. The optimal age and
the interval to start screening for a sympathetic PGL/PCC
could not be calculated, due to the relatively low number of
patients with these manifestations in our cohort. This rel-
atively low number of sympathetic PGL and PCC has also
been described in another Dutch report about the pheno-
type of SDHB mutation carriers in the Netherlands [20],
although in contrast to previous studies [6–8]. Neverthe-
less, the fact that four out of nine patients with a sympa-
thetic PGL or PCC were younger than 20 years of age
suggests that biochemical screening has to start at an earlier
age. Of notice, no renal cell carcinomas were detected in
our cohort despite a previously reported incidence of 14 %
among SDHB mutation carriers [12].
An important question is whether our findings can be
extrapolated to all SDHB mutation carriers, since the
penetrance of manifestations in our population is somewhat
lower than previously reported penetrance estimates,
showing a wide range varying from 18 to 95 % at age of
60 years (Table 4) [6–8, 10–12]. This wide variation in
penetrance rates is largely explained by differences
between the populations studied. The three studies with the
highest penetrance estimates [6, 7, 12] were mainly based
on index patients, which is expected to overestimate pen-
etrance frequency. Srirangalingam et al. [7] corrected for
this bias, by excluding the index patients, which resulted in
a considerably lower penetrance of 24 % (age not repor-
ted). The differences in penetrance frequencies could also
be caused by variation in genotypes and, therefore,
extrapolation to other genotypes might not be possible. In
our study we did not find a difference between the three
most frequent mutations in our study, but larger studies are
needed to further explore this hypothesis.




















HNPGL 19 11 1 5 0 1 0 0 1
Sympathetic
PGL/PCC
9 5 2 1 0 0 1 0 0
Malignant PGL 8 6 1 1 0 0 0 0 0
Unaffected 64 29 22 8 1 3 0 1 0
SDHB succinate dehydrogenase subunit B, HNPGL head and neck paraganglioma, PGL paraganglioma, PCC pheochromocytoma
Fig. 3 Natural logarithm of 1-cumulative proportion shown for
succinate dehydrogenase subunit B mutation carriers with a head and
neck paraganglioma (black line), corresponding to Poisson process
(grey line)
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Our results suggest that the screening for HNPGL in
SDHB mutation carriers might as well start at 27 years
instead of 18 years. This would result in a significant
decrease in financial costs and patient burden. Although in
certain families there is a request to start surveillance at an
earlier age for psychological reasons, the chance to detect a
HNPGL before the age of 27 years is very low (\2.5 %).
As also mentioned above, we can only draw this conclusion
for screening of HNPGL, screening for a sympathetic PGL
or PCC probably has to start at an earlier age.
The optimal surveillance interval was set at 5 %
detection probability which results in an interval of
3.2 years. This is in agreement with according to the cur-
rent guidelines [3]. A detection level of 5 % is comparable
to the yield of surveillance programs for breast and colon
cancer [21]. HNPGLs are benign and slow growing tumors,
although they can give rise to significant morbidity (i.e.
cranial nerve paralysis). Given the fact that the growth rate
of HNPGL is low (median doubling time of 10 years) and
only a small majority of these tumors (60 %) actually
grows [22], a detection level of 5 % seems justified. One
limitation of this assumption is that the risk of developing
metastases in patients with HNPGL is not clear from the
literature. In a meta-analysis of Hulsteijn et al. [14], the
risk of metastatic PGL was 17 % in patients with a SDHB
mutation, however it is not clear how many of these were
metastatic HNPGLs.
A limitation of our study is that we did not include a
sufficient number of patient to draw conclusions for sym-
pathetic PGL and PCC due to the limited penetrance of
sympathetic PGL and PCC observed in the Netherlands.
However, SDHB mutation carriers are rare and our cohort
with 91 carriers was large enough to draw solid statistical
conclusion about screening for HNPGL. Our findings need
to be confirmed in another large population of SDHB
mutation carriers to calculate optimal surveillance of the
manifestations for HNPGL in different genotypes and for
the manifestations sympathetic PGL and PCC. Another
limitation is the finding that two carriers were classified as
having an adrenal adenoma, although a non-functioning
PCC could not be ruled out since they were not operated
on.
In conclusion, we calculated the optimal surveillance for
HNPGL in SDHB mutation carriers by using a mathemat-
ical model. Based on these data the age to start could be
postponed to 27 years of age. These results may give rise to
reconsider the current guidelines regarding the screening of
SDHB mutation carriers.
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20 years 40 years 60 years 80 years Remarks
Schiavi et al. [10] 135 n.a. 1 % 8 % 18 % 30 % Families were excluded for which
information was available for the




Ricketts et al. [12] 295 n.a. 20 % 40 % 70 % – Tertiary referral center
Solis et al. [11] 41 1 10 % 35 % 35 % – One family with a large exon-1
mutation
Srirangalingam et al. [7] 32 34 % 25 % 50 % 95 % – Tertiary referral center
Benn et al. [8] 82 52 % 10 % 45 % 75 % 80 % Tertiary referral center
Neumann et al. [23] 42 60 % 30 % 55 % 95 % 100 % Tertiary referral center
Present cohort 23 % Tertiary referral center
Including index patients 91 6 % 18 % 35 % 49 %
Excluding index patients 70 0 % 2 % 12 % 22 %
SDHB succinate dehydrogenase subunit B, n.a. not applicable
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